GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omega Therapeutics Inc (NAS:OMGA) » Definitions » Equity-to-Asset

Omega Therapeutics (Omega Therapeutics) Equity-to-Asset : 0.23 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Omega Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Omega Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $41.35 Mil. Omega Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $183.68 Mil. Therefore, Omega Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.23.

The historical rank and industry rank for Omega Therapeutics's Equity-to-Asset or its related term are showing as below:

OMGA' s Equity-to-Asset Range Over the Past 10 Years
Min: -5.87   Med: 0.42   Max: 0.91
Current: 0.23

During the past 5 years, the highest Equity to Asset Ratio of Omega Therapeutics was 0.91. The lowest was -5.87. And the median was 0.42.

OMGA's Equity-to-Asset is ranked worse than
78.62% of 1567 companies
in the Biotechnology industry
Industry Median: 0.66 vs OMGA: 0.23

Omega Therapeutics Equity-to-Asset Historical Data

The historical data trend for Omega Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omega Therapeutics Equity-to-Asset Chart

Omega Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
-5.87 -2.30 0.86 0.73 0.28

Omega Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.79 0.42 0.35 0.28 0.23

Competitive Comparison of Omega Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Omega Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omega Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omega Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Omega Therapeutics's Equity-to-Asset falls into.



Omega Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Omega Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=58.016/204.366
=0.28

Omega Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=41.354/183.68
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Omega Therapeutics  (NAS:OMGA) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Omega Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Omega Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Omega Therapeutics (Omega Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
20 Acorn Park Drive, Cambridge, MA, USA, 02140
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using the epigenomic controllers, Omega is seeking to transform the practice of human medicine through highly selective and direct control of the human genome to treat and cure disease. It primarily operates in the U.S.
Executives
Michelle C Werner director C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Christian S Schade director MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
Richard A Young director, 10 percent owner C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE SUITE 300, CAMBRIDGE MA 02139
Flagship Pioneering Special Opportunities Fund Ii General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Rainer J. Boehm director C/O HUMANIGEN, INC., 1000 MARINA BOULEVARD, SUITE 250, BRISBANE CA 94005-1878
Joshua Reed officer: Chief Financial Officer C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Kevin Mcmanus officer: Chief Human Resources Officer C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Ling Zeng officer: See Remarks C/O DICERNA PHARMACEUTICALS, INC., 33 HAYDEN AVENUE, LEXINGTON MA 02421
Yan Moore officer: Chief Medical Officer C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
David A Berry director C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142
Flagship Ventures Fund V General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Roger Sawhney officer: Chief Financial Officer C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Flagship Pioneering Fund Vi General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142

Omega Therapeutics (Omega Therapeutics) Headlines

From GuruFocus